At Dartsbio, we are committed to developing products that bring new product, like DS002 Injection, to patients with serious diseases with no or limited treatment options.
Currently,Dartsbio does not offer an expanded access proaram and is not accepting expanded access requests for our investigational products, including DS002 Injection.
We understand patient interest in accessing DS002 Injection outside of clinical trials and prior to regulatory approval. However, participation in our clinical trials is currently the most appropriate way to access our investigational products.Please see Dartsbio Clinical Trials webpage(http://www.chinadrugtrials.org.cn/clinicaltrials.searchlist.dhtml) for publicly available information related to Dartsbio' ongoing clinical trials.
If you have any questions about Dartsbio'EA policy,please contact andy.zhou@dartsbio.com.
Phone
Email
EA Policies for Single Patient